- Home
- DTIL vs ATRA Comparison
DTIL vs ATRA Comparison
Compare DTIL & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- ATRA
- Stock Information
- Founded
- DTIL 2006
- ATRA 2012
- Country
- DTIL United States
- ATRA United States
- Employees
- DTIL N/A
- ATRA N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DTIL Health Care
- ATRA Health Care
- Exchange
- DTIL Nasdaq
- ATRA Nasdaq
- Market Cap
- DTIL 43.3M
- ATRA 42.5M
- IPO Year
- DTIL 2019
- ATRA 2014
- Fundamental
- Price
- DTIL $4.49
- ATRA $6.01
- Analyst Decision
- DTIL Strong Buy
- ATRA Buy
- Analyst Count
- DTIL 3
- ATRA 6
- Target Price
- DTIL $37.67
- ATRA $25.70
- AVG Volume (30 Days)
- DTIL 134.4K
- ATRA 50.2K
- Earning Date
- DTIL 03-26-2025
- ATRA 05-08-2025
- Dividend Yield
- DTIL N/A
- ATRA N/A
- EPS Growth
- DTIL N/A
- ATRA N/A
- EPS
- DTIL 1.04
- ATRA N/A
- Revenue
- DTIL $68,696,000.00
- ATRA $128,940,000.00
- Revenue This Year
- DTIL N/A
- ATRA N/A
- Revenue Next Year
- DTIL $58.46
- ATRA $43.69
- P/E Ratio
- DTIL $4.32
- ATRA N/A
- Revenue Growth
- DTIL 40.98
- ATRA 1404.02
- 52 Week Low
- DTIL $3.61
- ATRA $5.40
- 52 Week High
- DTIL $15.97
- ATRA $20.83
- Technical
- Relative Strength Index (RSI)
- DTIL 38.26
- ATRA 36.60
- Support Level
- DTIL $4.25
- ATRA $6.53
- Resistance Level
- DTIL $5.72
- ATRA $6.90
- Average True Range (ATR)
- DTIL 0.38
- ATRA 0.43
- MACD
- DTIL -0.07
- ATRA -0.00
- Stochastic Oscillator
- DTIL 16.33
- ATRA 16.32
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).